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Lancet). Analysed treatment options were no antiviral
therapy (NoAVT), peginterferon alfa-2b plus ﬁxed dosage
of ribavirin (Peg-fR), and peginterferon alfa-2b plus
weight-based dosage of ribavirin (Peg-wbR). Examined
scenarios were: 1) full dosing AVT for 48 weeks (Full-
AVT); 2) stoppage of AVT in HCV-positive patients after
24 weeks (Stop-AVT); 3) consideration of AVT stoppage
algorithm plus actual dose reductions/ discontinuations
(Actual-AVT); and 4) net lifetime costs after subtracting
future savings due to prevented advanced liver disease
(Life). A validated Markov model (German Hepatitis 
C Model) was used to project future costs of CHC.
RESULTS: Full-AVT costs were €21,600 for Peg-fR and
€23,700 for Peg-wbR. Consideration of stoppage algo-
rithm and actual drug utilisation lead to 8%–33% reduc-
tions in expected AVT costs. In the lifetime analysis, AVT
costs were offset by savings from preventing future
disease by more than 85%, and incremental costs for AVT
were less than €2100. After applying a 3% annual dis-
count rate as recommended for pharmacoeconomic
studies (Life-D), future savings still offset AVT costs by
47% and the discounted lifetime costs for NoAVT, 
Peg-fR, and Peg-wbR were €14,100, €21,800, and
€22,400, respectively. CONCLUSIONS: Health policy
decision making for CHC should consider actual
expected AVT costs based on routine clinical management
algorithms and a time horizon beyond the ﬁrst year.
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OBJECTIVES: In European countries, incidence and
prevalence of End Stage Renal Disease (ESRD) are in-
creasing. Discrepancies between countries and regions
exist in the use of renal replacement therapies (RRT). 
Literature analysis, comparing haemodialysis (HD) to
peritoneal dialysis (PD) in terms of mortality/morbidity
and of patients’ preferences provides no evidence relative
to understanding differences in the provision of the
various treatments offered. Due to the high costs and
organizational issues of RRT, predicting future needs is
essential for nephrologists and Health care authorities.
Our aim was to project the impact of various therapeu-
tic strategies on the number of ESRD patients and their
distribution between existing dialysis techniques.
METHODS: We projected the ESRD incidence and
prevalence rates up until the year 2008. A Markov model
was built using data from French national registers
(French speaking PD register, French transplants organi-
zation) and speciﬁc surveys (Federation of non-proﬁt
private hospital establishments). Six Markov states were
deﬁned: No ESRD, in-centre HD (CHD), out-centre HD
(OCHD), PD, Transplantation (T) and Death (D). Tran-
sition probabilities were assessed considering a one-year
Markov cycle. A sensitivity analysis was performed on
fundamental assumptions. RESULTS: The number of
ESRD patients was projected to rise from 45,000 to
57,600, if 5% of incident patients at start of RRT were
treated by PD, 58% by HDC, 22% by OCHD, and 4%
transplanted. A substantial modiﬁcation of the initial 
distribution of incident patients was needed to have a 
signiﬁcant impact on the ﬁnal distribution of patients
between techniques. An increase of 5% to 20% of inci-
dent patients initially treated by PD, resulted in a rise
from 6.7% to 8.6% of prevalent patients ﬁnally treated
by that technique. CONCLUSIONS: ESRD is a French
Health care priority. This Markov model could be very
useful to planners in elaborating their Health care orga-
nizational schemes for the coming 5 years.
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OBJECTIVES: To determine the economic impact of
childhood varicella vaccination in France. METHODS:
This analysis is based on an epidemiological model of
VZV dynamics using Varivax efﬁcacy data. Epidemio-
logical and cost data (€2002) are based on French
sources. Three vaccination strategies have been analyzed
(S1: routine children vaccination alone, completed by 
S2: catch up program for 6 year-olds during 6 years, or
S3: massive catch up for 2–11 year-olds the ﬁrst year 
of vaccine marketing), for 3 vaccination coverage rates
(VCR), 45%, 70% and 90% achieved in 5 years. 
Perspectives considered are: societal perspective limited to
direct medical costs (SPD), or including indirect costs
(SPT), and Social Security perspective (SS). RESULTS:
Achieving a 90% VCR should yield, on a 50 years time
frame, a 85% decrease in varicella cases in average, and
prevent 27,000 to 33,000 varicella-related complications
annually (13,000 to 15,000 for a 45% VCR). Such a
program also leads in the base case to a decrease of total
costs (-52% for a 90% VCR), direct medical costs (-4%)
and SS costs (-10%) associated to varicella. The reduc-
tion of total costs is robust to the sensitivity analysis per-
formed; for SS perspective, the worst case scenario for
cost parameters leads to a cost per life year gained of
€6017 in 90% VCR. A massive catch up the ﬁrst year of
vaccine marketing is the one having the biggest impact on
varicella complications and costs: overall about (base
case) 80,000 additional complications prevented and a
saving of €147 million in total costs compared to routine
vaccination alone for a 90% VCR. CONCLUSION:
Routine childhood varicella vaccination in France is cost-
saving from all perspectives in the base case if high vac-
cination coverage is achieved, and remains cost-effective
in most conservative scenarios.
